drugset / Trial / NCT05004064
Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, single-arm, open-label, multicentre study of acalabrutinib and rituximab for elderly or frail patients with previously untreated mantle cell lymphoma.
Timeline
- Start
- 2023-11-30
- Primary completion
- 2026-06-08
- Completion
- 2028-06-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | 100 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |